Drugnews|藥時事

BioLASCO

樂斯科生物科技股份有限公司

6662 · TPEx-listed

BioLASCO focuses on laboratory animals, testing services, pathology / toxicology, equipment and reagents, as of 2026-11-01.

Pipeline and products

No publicly disclosed new-drug pipeline.

Key events

No public update recorded for this period.

Related Drugnews articles

No related articles in this language.